Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...

With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal ...

A popular awareness campaign now in its second year that encouraged people to get flu vaccines to reduce their risk of severe ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...